Spots Global Cancer Trial Database for ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer

Official Title: ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer: A Prospective Multicenter Randomized Controlled Clinical Trial

Study ID: NCT05815082

Conditions

Colorectal Cancer

Liver Metastases

Circulating Tumor Cell

Chemotherapy Effect

Interventions

Colorectal cancer resection combined with liver metastasis resection.

FOLFOX chemotherapy regimen

Study Description

Brief Summary: The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is non-inferior to adjuvant chemotherapy in postoperative ctDNA-negative resectable colorectal cancer liver metastasis patients.Participants will undergo ctDNA testing after resection of colorectal cancer liver metastasis, and will be randomly assigned to receive adjuvant chemotherapy or "watching and waiting" treatment strategy. The researchers will compare the outcomes between the two groups to see if the PFS between the two groups is similar.

Detailed Description: